| Literature DB >> 35055245 |
Mariaconcetta Sicurella1, Maddalena Sguizzato1, Paolo Mariani2, Alessia Pepe2, Anna Baldisserotto3, Raissa Buzzi3, Nicolas Huang4, Fanny Simelière4, Sam Burholt5, Peggy Marconi1, Elisabetta Esposito1.
Abstract
Herpes simplex virus type 1 infection commonly affects many people, causing perioral sores, as well as severe complications including encephalitis in immunocompromised patients. The main pharmacological approach involves synthetic antiviral drugs, among which acyclovir is the golden standard, often leading to resistant virus strains under long-term use. An alternative approach based on antiviral plant-derived compounds, such as quercetin and mangiferin, demonstrated an antiviral potential. In the present study, semisolid forms for cutaneous application of quercetin and mangiferin were designed and evaluated to treat HSV-1 infection. Phosphatidylcholine- and poloxamer-based gels were produced and characterized. Gel physical-chemical aspects were evaluated by rheological measurements and X-ray diffraction, evidencing the different thermoresponsive behaviors and supramolecular organizations of semisolid forms. Quercetin and mangiferin diffusion kinetics were compared in vitro by a Franz cell system, demonstrating the different gel efficacies to restrain the polyphenol diffusion. The capability of gels to control polyphenol antioxidant potential and stability was evaluated, indicating a higher stability and antioxidant activity in the case of quercetin loaded in poloxamer-based gel. Furthermore, a plaque reduction assay, conducted to compare the virucidal effect of quercetin and mangiferin loaded in gels against the HSV-1 KOS strain, demonstrated the suitability of poloxamer-based gel to prolong the polyphenol activity.Entities:
Keywords: HSV-1; gels; in vitro diffusion; infection control; lecithin; localized drug action; mangiferin; poloxamer; polyphenols; quercetin
Year: 2022 PMID: 35055245 PMCID: PMC8780422 DOI: 10.3390/nano12020227
Source DB: PubMed Journal: Nanomaterials (Basel) ISSN: 2079-4991 Impact factor: 5.076
Composition of semisolid vehicles employed for this study.
| Vehicle Composition (% | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Component | OG | POL | POG | OG-QT | POL-QT | POG-QT | OG-MG | POL-MG | POG-MG |
| PC 1 | 15.60 | - | 4.68 | 15.60 | - | 4.68 | 15.60 | - | 4.68 |
| P-407 2 | - | 20.0 | 14.00 | - | 20.00 | 14.00 | - | 20.0 | 14.00 |
| IPP 3 | 82.51 | - | 24.82 | 82.46 | - | 24.82 | 82.46 | - | 24.82 |
| water | 1.44 | 80.0 | 56.50 | 1.44 | 79.95 | 56.45 | 1.44 | 79.95 | 56.45 |
| QT 4 | - | - | - | 0.05 | 0.05 | 0.05 | - | - | - |
| MG 5 | - | - | - | - | - | - | 0.05 | 0.05 | 0.05 |
1: soy phosphatidylcholine; 2: poloxamer 407; 3: isopropylpalmitate; 4: quercetin; 5: mangiferin.
Figure 1Evolution of elastic (G′) and viscous (G″) moduli as a function of temperature for OG (a), POL (b) and POG (c).
Rheological and diffraction parameters of the indicated forms.
| Vehicle | Tsol–gel
1 | Structure 2 | SAXS Repeat | WAXS Repeat Distance (Å) 2 |
|---|---|---|---|---|
| OG | 11.5 ± 0.1 | Disordered micellar | - | 4.59 |
| POL | 20.8 ± 0.7 | Cubic (space group Q223) | 282.08 | 3.29 |
| POG | 16.4 ± 2.1 | Ordered micellar | 196.34 | 3.34–4.83 |
1: sol–gel transition temperature; 2: determined at 25 °C.
Figure 2Small-angle X-ray scattering profiles of OG (a), POL (b) and POG (c). The thin vertical lines superposed to the b SAXS profile indicate the position of the Bragg peaks permitted for the Pm3n symmetry; note that Bragg peaks could be absent for other reasons than symmetry [41].
Figure 3Wide-angle X-ray scattering profiles of OG (a), POL (b) and POG (c).
Figure 4In vitro diffusion kinetics of QT (a) and MG (b) loaded in OG (circles), POL (squares), POG (triangles) or solubilized in ethanol/water, 30:70 v/v (crosses), as determined by Franz cells associated with PTFE membranes.
Diffusion parameters of the indicated formulations.
| Vehicles | F 1 ± s.d. | QT | MG | D 2 ± s.d. | Q7
3 ± s.d. | Reduction |
|---|---|---|---|---|---|---|
| OG-QT | 2.84 ± 1.1 | 0.5 | - | 5.68 ± 2.2 | 20 ± 4 | 21.5 |
| POL-QT | 9.16 ± 2.7 | 0.5 | - | 18.32 ± 5.4 | 66 ± 11 | 6.6 |
| POG-QT | 5.42 ± 4.3 | 0.5 | - | 10.84 ± 8.6 | 39 ± 17 | 12.2 |
| SOL-QT | 61.06 ± 2.8 | 0.5 | - | 122.13 ± 5.6 | 403 ± 32 | - |
| OG-MG | 38.69 ± 6.8 | - | 0.5 | 77.38 ± 13.6 | 257.14 ± 38 | 1.96 |
| POL-MG | 17.64 ± 2.4 | - | 0.5 | 35.28 ± 4.8 | 128.57 ± 10 | 4.3 |
| POG-MG | 5.02 ± 1.1 | - | 0.5 | 10.04 ± 2.2 | 36.43 ± 4 | 15.11 |
| SOL-MG | 75.86 ± 12 | - | 0.5 | 151.72 ± 24 | 271.43 ± 23 | - |
1: Flux; 2: diffusion coefficient; 3: drug diffused after 7 h; 4: reduction in diffusion with respect to SOL-MG or SOL-QT; data are the mean of 6 independent Franz cell experiments.
Figure 5(a) QT (light gray) and MG (gray) content in formulations stored for 120 days at 25 °C, expressed as percentage with respect to the initial drug content. (b) Antioxidant capacity of QT (light gray) and MG (gray), as detected by ACL test, referring to μmol TE/g of sample.
Antioxidant and virucidal parameters of the indicated formulations.
| Vehicles | ACL (μmol TE/g) | Plaque Reduction | |
|---|---|---|---|
| 1 h | 6 h | ||
| OG-QT | 4.52 ± 0.34 | 50.0 ± 1.0 | 50.0 ± 1.0 |
| POL-QT | 6.76 ± 0.14 | 47.5 ± 1.0 | 93.5 ± 0.75 |
| POG-QT | 4.80 ± 0.23 | 46.0 ± 0.75 | 80.0 ± 0.75 |
| SOL- QT | 3.82 ± 0.05 | 89.0 ± 1.0 | 76.0 ± 1.0 |
| OG-MG | 2.48 ± 0.02 | - | - |
| POL-MG | 0.87 ± 0.02 | 40.0 ± 1.7 | 94.0 ± 0.74 |
| POG-MG | 1.26 ± 0.06 | 40.0 ± 1.0 | 98.0 ± 0.62 |
| SOL-MG | 0.65 ± 0.04 | 40.0 ± 1.7 | 93.0 ± 0.74 |
QT and MG: 0.5 mg/mL.
Figure 6Virucidal activity of QT-containing (a) and MG-containing (b) formulations, expressed as percentage of viral reduction measured after 1 (light gray) and 6 (gray) h of contact between formulations and KOS strain at 35 °C. Data represent the mean of 3 independent experiments, * p values < 0.05.